Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers

被引:13
作者
Genestie, Catherine [1 ,2 ]
Auguste, Aurelie [2 ]
Al Battal, Miriam [1 ]
Scoazec, Jean-Yves [1 ,3 ]
Gouy, Sebastien [4 ]
Lacroix, Ludovic [5 ]
Morice, Philippe [3 ,4 ]
Pautier, Patricia [6 ]
Leary, Alexandra [2 ,6 ]
Devouassoux-Shisheboran, Mojgan [7 ,8 ]
机构
[1] Gustave Roussy, Dept Pathol, Villejuif, France
[2] Gustave Roussy, INSERM 981, Canc Campus, Villejuif, France
[3] Univ Paris Saclay, Fac Med Bicetre, Le Kremlin Bicetre, France
[4] Gustave Roussy, Dept Surg, Villejuif, France
[5] Gustave Roussy, Dept Tumor Genet, Villejuif, France
[6] Gustave Roussy, Dept Med, Villejuif, France
[7] Univ Claude Bernard Lyon 1, Dept Pathol, Villeurbanne, France
[8] Ctr Hosp Lyon Sud, Dept Pathol, 165 Chemin Grand Revoyet, F-69495 Pierre Benite, France
关键词
Mucinous tumor; Ovary; Mucinous borderline; Mucinous carcinoma; KRAS; TP53; Microinvasion; Grade; BORDERLINE TUMORS; INTESTINAL-TYPE; RECOMMENDATIONS; CARCINOMAS; MUTATIONS;
D O I
10.1007/s00428-020-02939-w
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The morphological distinction between the various types of mucinous ovarian tumors has major prognostic implications but may be challenging. The aims of our study were to describe inter-observer reproducibility in the morphological diagnosis of mucinous ovarian tumors, to evaluate the clinical relevance of possible diagnostic discrepancies, and to identify molecular abnormalities correlated with the histological type. Seventy-nine ovarian mucinous borderline tumors (MOB) and either expansile or infiltrative carcinomas (MOC) were independently reviewed by two gynecological pathologists. Molecular analysis was performed in 32 cases. Concordance between the two pathologists was reached in 67 cases (k: 0.78). The main discrepancies (8/12) were the evaluation of nuclear grade 3 or that of microfoci (< 5 mm) of infiltrative-type carcinoma in an otherwise typical expansile MOC. Our follow-up analysis showed that infiltrative MOC had a lower overall survival (OS) (p < 0.0024) and progression-free survival (PFS) (p = 0.0060) as compared with MOB and expansile MOC. The presence of nuclear grade 3 or microfoci (< 5 mm) of infiltrative-type pattern of invasion in an otherwise typical expansile MOC did not alter the prognosis as compared with expansile MOC without these features, in terms of OS (p < 0.0028) and PFS (p = 0.0074).KRASmutations were more frequent in MOB (71%), than in expansile (50%) and infiltrative MOC (14%). In contrast, the prevalence ofTP53mutation was lower in MOB (43%), than in expansile (58%) and infiltrative MOC (71%). Our results confirm that in MOC, the expansile pattern of invasion is associated with a better prognosis than extensive (> 5 mm) infiltrative-type pattern of invasion. No specific or sensitive molecular profile might help in the differential diagnosis of mucinous ovarian tumors.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 19 条
  • [1] Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas
    Anglesio, Michael S.
    Kommoss, Stefan
    Tolcher, Mary C.
    Clarke, Blaise
    Galletta, Laura
    Porter, Henry
    Damaraju, Sambasivarao
    Fereday, Sian
    Winterhoff, Boris J.
    Kalloger, Steve E.
    Senz, Janine
    Yang, Winnie
    Steed, Helen
    Allo, Ghassan
    Ferguson, Sarah
    Shaw, Patricia
    Teoman, Attila
    Garcia, Joaquin J.
    Schoolmeester, John K.
    Bakkum-Gamez, Jamie
    Tinker, Anna V.
    Bowtell, David D.
    Huntsman, David G.
    Gilks, C. Blake
    McAlpine, Jessica N.
    [J]. JOURNAL OF PATHOLOGY, 2013, 229 (01) : 111 - 120
  • [2] The molecular origin and taxonomy of mucinous ovarian carcinoma
    Cheasley, Dane
    Wakefield, Matthew J.
    Ryland, Georgina L.
    Allan, Prue E.
    Alsop, Kathryn
    Amarasinghe, Kaushalya C.
    Ananda, Sumitra
    Anglesio, Michael S.
    Au-Yeung, George
    Bohm, Maret
    Bowtell, David Dl
    Brand, Alison
    Chenevix-Trench, Georgia
    Christie, Michael
    Chiew, Yoke-Eng
    Churchman, Michael
    DeFazio, Anna
    Demeo, Renee
    Dudley, Rhiannon
    Fairweather, Nicole
    Fedele, Clare G.
    Fereday, Sian
    Fox, Stephen B.
    Gilks, C. Blake
    Gourley, Charlie
    Hacker, Neville F.
    Hadley, Alison M.
    Hendley, Joy
    Ho, Gwo-Yaw
    Hughes, Siobhan
    Hunstman, David G.
    Hunter, Sally M.
    Jobling, Tom W.
    Kalli, Kimberly R.
    Kaufmann, Scott H.
    Kennedy, Catherine J.
    Kobel, Martin
    Le Page, Cecile
    Li, Jason
    Lupat, Richard
    McNally, Orla M.
    McAlpine, Jessica N.
    Mes-Masson, Anne-Marie
    Mileshkin, Linda
    Provencher, Diane M.
    Pyman, Jan
    Rahimi, Kurosh
    Rowley, Simone M.
    Salazar, Carolina
    Samimi, Goli
    [J]. NATURE COMMUNICATIONS, 2019, 10 (1)
  • [3] Networking for ovarian rare tumors: a significant breakthrough improving disease management
    Chiannilkulchai, N.
    Pautier, P.
    Genestie, C.
    Bats, A. S.
    Vacher-Lavenu, M. C.
    Devouassoux-Shisheboran, M.
    Treilleux, I.
    Floquet, A.
    Croce, S.
    Ferron, G.
    Mery, E.
    Pomel, C.
    Penault-Llorca, F.
    Lefeuvre-Plesse, C.
    Henno, S.
    Leblanc, E.
    Lemaire, A. S.
    Averous, G.
    Kurtz, J. E.
    Ray-Coquard, I.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1274 - 1279
  • [4] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
    Colombo, N.
    Sessa, C.
    du Bois, A.
    Ledermann, J.
    McCluggage, W. G.
    McNeish, I.
    Morice, P.
    Pignata, S.
    Ray-Coquard, I.
    Vergote, I.
    Baert, T.
    Belaroussi, I.
    Dashora, A.
    Olbrecht, S.
    Planchamp, F.
    Querleu, D.
    Baert, T.
    Banerjee, S.
    Belaroussi, I.
    Blecharz, P.
    Bruchim, I.
    Cibula, D.
    Colombo, N.
    Concin, N.
    Davidson, B.
    Dashora, A.
    Devouassoux-Shisheboran, M.
    du Bois, A.
    Ferrero, A.
    Glasspool, R.
    Gonzalez-Martin, A.
    Heinzelmann-Schwarz, V.
    Joly, F.
    Kim, J. W.
    Kridelka, F.
    Ledermann, J.
    Lorusso, D.
    Mahner, S.
    McCluggage, W. G.
    McNeish, I.
    Mikami, M.
    Mirza, M. R.
    Morice, P.
    Nicum, S.
    Olbrecht, S.
    O'Donnell, D. M.
    Pautier, P.
    Planchamp, F.
    Pignata, S.
    Querleu, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (05) : 672 - 705
  • [5] Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO
  • [6] 2-T
  • [7] Mucinous ovarian tumors of mullerian-type:: An analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas
    Dubé, V
    Roy, M
    Plante, M
    Renaud, MC
    Têtu, B
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2005, 24 (02) : 138 - 146
  • [8] Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma
    Gilks, C. Blake
    Ionescu, Diana N.
    Kalloger, Steve E.
    Koebel, Martin
    Irving, Julie
    Clarke, Blaise
    Santos, Jennifer
    Le, Nhu
    Moravan, Veronika
    Swenerton, Kenneth
    [J]. HUMAN PATHOLOGY, 2008, 39 (08) : 1239 - 1251
  • [9] Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type
    Gouy, Sebastien
    Saidani, Marine
    Maulard, Amandine
    Bach-Hamba, Slim
    Bentivegna, Enrica
    Leary, Alexandra
    Pautier, Patricia
    Devouassoux-Shisheboran, Mojgan
    Genestie, Catherine
    Morice, Philippe
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (03) : 493 - 499
  • [10] Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
    Kobel, Martin
    Piskorz, Anna M.
    Lee, Sandra
    Lui, Shuhong
    LePage, Cecile
    Marass, Francesco
    Rosenfeld, Nitzan
    Masson, Anne-Marie Mes
    Brenton, James D.
    [J]. JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2016, 2 (04): : 247 - 258